The extent of surgery for gastric cancer has been debated since Billroth performed his first gastrectomy in 1881. This review gives an overview of the available literature on the extent of gastrectomy and lymphadenectomy for advanced resectable gastric cancer. Subtotal gastrectomy is associated with lower morbidity and mortality compared with total gastrectomy, without compromising long-term survival. However, a positive resection margin decreases the chance of curation. Frozen section examination may prevent this. For poorly differentiated singlet ring cell tumors, there may be an argument to perform a total gastrectomy in all cases. In 1981, the Japanese Research Society for the Study of Gastric Cancer provided guidelines for the standardization of surgical treatment and pathological evaluation of gastric cancer. Since then, D2 lymph node dissections have become the standard of care in Japan. Because of the superior stage-specific survival rates in Japan, a D2 dissection was evaluated in several Western randomized controlled trials, but no survival benefit was found for a D2 over a D1 dissection. This might be explained by the increased mortality in the D2 dissection groups which might be the result of a standard pancreaticosplenectomy and low experience with D2 dissections. Adding the removal of the para-aortic nodes to a D2 dissection does not further improve survival. The removal of lymph node stations 10 and 11 by splenectomy showed an increased morbidity, no survival benefit, and a very poor prognosis if lymph nodes were affected. Therefore, pancreaticosplenectomy should only be performed in cases of tumor invasion into these organs. A D2 dissection without routine splenectomy and pancreatic tail resection in experienced hands should be considered standard of care for advanced resectable gastric cancer, both in Asian and in Western patients. Centralization and auditing may further improve outcomes after gastrectomy.

1.
Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancerdisparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-2150.
2.
Yamaoka Y, Kato M, Asaka M: Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med 2008;47:1077-1083.
3.
Hamashima C, Shibuya D, Yamazaki H, et al: The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008;38:259-267.
4.
Hundahl A, Phillips JL, Menck HR, et al: The National Cancer Data Base Report on poor survival of US gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal, and the ‘different disease' hypothesis. Cancer 2000;88:921-932.
5.
Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
6.
Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
7.
Okines A, Verheij M, Allum W, Cunningham D, Cervantes A, ESMO Guidelines Working Group: Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5):v50-v54.
8.
NCCN: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Gastric Cancer, Version 2, 2011. http://www.nccn.org.
9.
Viste A, Haugstvedt T, Eide GE, Soreide O: Postoperative complications and mortality after surgery for gastric cancer. Ann Surg 1988;207:7-12.
10.
Bottcher K, Siewert JR, Roder JD, Busch R, Hermanek P, Meyer HJ: Risiko der chirurgischen Therapie des Magencarcinoms in Deutschland: Ergebnisse der Deutschen Magencarcinom-Studie 1992. Chirurg 1994;65:298-306.
11.
Gouzi JL, Huguier M, Fagniez PL, et al: Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 1989;209:162-166.
12.
Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L: Subtotal versus total gastrectomy for gastric cancer: five year survival rates in a multicenter randomized Italian trial. Gastrointestinal Tumor Study Group. Ann Surg 1999;230:170-178.
13.
Bonenkamp JJ, van de Velde CJ, Songun I, et al: Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745-748.
14.
Cuschieri A, Weeden S, Fielding J, et al: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522-1530.
15.
Sasako M: Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Br J Surg 1997;84:1567-1571.
16.
Songun I, Bonenkamp JJ, Hermans J, van Krieken JH, van de Velde CJ: Prognostic value of resection-line involvement in patients undergoing curative resections for gastric cancer. Eur J Cancer 1996;32:433-437.
17.
Kijitani T: Japanese Research Society for the Study of Gastric Cancer. The general rules for gastric cancer study and pathology. Jap J Surg 1981;11:127-145.
18.
Maruyama K, Okabayashi K, Kinoshita T: Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418-425.
19.
Dent DM, Madden MV, Price SK: Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988;75:110-112.
20.
Robertson CS, Chung SC, Woods SD, et al: A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994;220:176-182.
21.
Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Dutch Gastric Cancer trial group: Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-914.
22.
Hartgrink HH, van de Velde CJ, Putter H, et al: Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. J Clin Oncol 2004;22:2069-2077.
23.
Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ: Gastric cancer - seminar. Lancet 2009;374:477-490.
24.
Songun I, Putter H, Meershoek-Klein Kranenbarg E, Sasako M, van de Velde CJ: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-449.
25.
McCulloch P, Nita ME, Kazi H, Gama-Rodrigues J: Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2004;4:CD001964.
26.
Degiuli M, Sasako M, Ponti A, Italian Gastric Cancer Study Group: Br J Surg 2010;97:643-649.
27.
Wu CW, Hsiung CA, Lo SS, et al: Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol 2006;7:309-315.
28.
Sasako M, Sano T, Yamamoto S, et al: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-462.
29.
Kampschoer GH, Maruyama K, van de Velde CJ, Sasako M, Kinoshita T, Okabayashi K: Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients. Br J Surg 1989;76:905-908.
30.
Peeters KC, Hundahl SA, Kranenbarg EK, Hartgrink HH, van de Velde CJ: Low Maruyama index surgery for gastric cancer: blinded re-analysis of the Dutch D1-D2 trial. World J Surg 2005;29:1576-1584.
31.
Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T, Southwest Oncology Group and the Gastric Intergroup: Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 2002;9:278-286.
32.
Furakawa H, Hiratsuka M, Ishikawa O, et al: Total gastrectomy with dissection of lymph nodes along the splenic artery: a pancreas preserving method. Ann Surg 2000;7:669-673.
33.
Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F: A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002;131:401-407.
34.
Yu W, Choi GS, Chung HY: Randomised clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006;93:559-563.
35.
Brar SS, Seevaratnam R, Cardoso R, Law C, Helyer L, Coburn N: A systematic review of spleen and pancreas preservation in extended lymphadenectomy for gastric cancer. Gastric Cancer 2012;15(suppl 1):S89-S99.
36.
Sano T, Yamamoto S, Sasako M: Randomised controlled trial to evaluate splenectomy in total gastrectomy fgor gastric adenocarcinoma: Japan Clinical Oncology Group Study JCOG 0110-MF. Jpn J Clin Oncol 2002;32:363-364.
37.
Krijnen P, den Dulk M, Meershoek-Klein Kranenbarg E, Jansen-Lansheer ML, van de Velde CJ: Improved survival after resectable non-cardia gastric cancer in the Netherlands: the importance of surgical training and quality control. Eur J Surg Oncol 2009;35:715-720.
38.
Birkmeyer JD, Siewers AE, Finlayson EV, et al: Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-1137.
39.
Jensen LS, Nielsen H, Mortensen PB, Pilegaard HK, Johnsen SP: Enforcing centralization for gastric cancer in Denmark. Eur J Surg Oncol 2010;36:S50-S54.
40.
Birgisson H, Talback M, Gunnarson U, Pahlman L, Glimelius B: Improved survival in cancer of the colon and rectum in Sweden. Eur J Surg Oncol 2005;31:845-853.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.